Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(2), 406-418; doi:10.3390/ph3020406
Review

Deregulation of Interferon Signaling in Malignant Cells

,  and *
Received: 10 December 2009; in revised form: 28 January 2010 / Accepted: 1 February 2010 / Published: 4 February 2010
(This article belongs to the Special Issue Interferons)
View Full-Text   |   Download PDF [1015 KB, uploaded 4 February 2010]
Abstract: Interferons (IFNs) are a family of cytokines with potent antiproliferative, antiviral, and immunomodulatory properties. Much has been learned about IFNs and IFN-activated signaling cascades over the last 50 years. Due to their potent antitumor effects in vitro and in vivo, recombinant IFNs have been used extensively over the years, alone or in combination with other drugs, for the treatment of various malignancies. This review summarizes the current knowledge on IFN signaling components and pathways that are deregulated in human malignancies. The relevance of deregulation of IFN signaling pathways in defective innate immune surveillance and tumorigenesis are discussed.
Keywords: interferon; signaling pathways; cancer interferon; signaling pathways; cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Katsoulidis, E.; Kaur, S.; Platanias, L.C. Deregulation of Interferon Signaling in Malignant Cells. Pharmaceuticals 2010, 3, 406-418.

AMA Style

Katsoulidis E, Kaur S, Platanias LC. Deregulation of Interferon Signaling in Malignant Cells. Pharmaceuticals. 2010; 3(2):406-418.

Chicago/Turabian Style

Katsoulidis, Efstratios; Kaur, Surinder; Platanias, Leonidas C. 2010. "Deregulation of Interferon Signaling in Malignant Cells." Pharmaceuticals 3, no. 2: 406-418.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert